Literature DB >> 27055612

Screening Medications for the Treatment of Cannabis Use Disorder.

L V Panlilio1, Z Justinova1, J M Trigo2, B Le Foll3.   

Abstract

Cannabis use has been increasingly accepted legally and in public opinion. However, cannabis has the potential to produce adverse physical and mental health effects, and cannabis use disorder (CUD) occurs in a substantial percentage of both occasional and daily cannabis users. Many people have difficulty discontinuing use despite receiving treatment. Therefore, it would be beneficial to develop safe and effective medications for treating CUD. To achieve this, methods have been developed for screening and evaluating potential medications using animal models and controlled experimental protocols in human volunteers. In this chapter, we describe: (1) animal models available for assessing the effect of potential medications on specific aspects of CUD, (2) the main findings obtained so far with these animal models, (3) the approaches used to assess potential medications in humans in laboratory experiments and clinical trials, and (4) the effectiveness of several potential pharmacotherapies on particular aspects of CUD modeled in these human studies.
© 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Animal models; Cannabinoids; Clinical trials; Marijuana; Relapse; Spice drugs; THC; Withdrawal

Mesh:

Substances:

Year:  2016        PMID: 27055612      PMCID: PMC4990353          DOI: 10.1016/bs.irn.2016.02.005

Source DB:  PubMed          Journal:  Int Rev Neurobiol        ISSN: 0074-7742            Impact factor:   3.230


  120 in total

Review 1.  Functionally selective cannabinoid receptor signalling: therapeutic implications and opportunities.

Authors:  Barbara Bosier; Giulio G Muccioli; Emmanuel Hermans; Didier M Lambert
Journal:  Biochem Pharmacol       Date:  2010-03-03       Impact factor: 5.858

Review 2.  Cannabis smoking and respiratory health: consideration of the literature.

Authors:  Peter Gates; Adam Jaffe; Jan Copeland
Journal:  Respirology       Date:  2014-05-15       Impact factor: 6.424

3.  Marijuana withdrawal among adults seeking treatment for marijuana dependence.

Authors:  A J Budney; P L Novy; J R Hughes
Journal:  Addiction       Date:  1999-09       Impact factor: 6.526

4.  Naltrexone does not attenuate the effects of intravenous Δ9-tetrahydrocannabinol in healthy humans.

Authors:  Mohini Ranganathan; Michelle Carbuto; Gabriel Braley; Jaqueline Elander; Edward Perry; Brian Pittman; Rajiv Radhakrishnan; Richard A Sewell; Deepak C D'Souza
Journal:  Int J Neuropsychopharmacol       Date:  2012-01-16       Impact factor: 5.176

5.  Evaluation of WIN 55,212-2 self-administration in rats as a potential cannabinoid abuse liability model.

Authors:  Timothy W Lefever; Julie A Marusich; Kateland R Antonazzo; Jenny L Wiley
Journal:  Pharmacol Biochem Behav       Date:  2014-01-09       Impact factor: 3.533

6.  Treatment of cannabis dependence using escitalopram in combination with cognitive-behavior therapy: a double-blind placebo-controlled study.

Authors:  A M Weinstein; H Miller; I Bluvstein; E Rapoport; S Schreiber; R Bar-Hamburger; M Bloch
Journal:  Am J Drug Alcohol Abuse       Date:  2014-01       Impact factor: 3.829

Review 7.  Is There a Place for Off-Label Pharmacotherapy in Cannabis Use Disorder? A Review on Efficacy and Safety.

Authors:  Vincent Laprevote; Raymund Schwan; Thomas Schwitzer; Benjamin Rolland; Johannes Thome
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

8.  The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys.

Authors:  Zuzana Justinova; Gianluigi Tanda; Patrik Munzar; Steven R Goldberg
Journal:  Psychopharmacology (Berl)       Date:  2003-12-11       Impact factor: 4.530

9.  Cannabis withdrawal in chronic, frequent cannabis smokers during sustained abstinence within a closed residential environment.

Authors:  Dayong Lee; Jennifer R Schroeder; Erin L Karschner; Robert S Goodwin; Jussi Hirvonen; David A Gorelick; Marilyn A Huestis
Journal:  Am J Addict       Date:  2014 May-Jun

10.  Enhanced self-administration of the CB1 receptor agonist WIN55,212-2 in olfactory bulbectomized rats: evaluation of possible serotonergic and dopaminergic underlying mechanisms.

Authors:  Petra Amchova; Jana Kucerova; Valentina Giugliano; Zuzana Babinska; Mary T Zanda; Maria Scherma; Ladislav Dusek; Paola Fadda; Vincenzo Micale; Alexandra Sulcova; Walter Fratta; Liana Fattore
Journal:  Front Pharmacol       Date:  2014-03-20       Impact factor: 5.810

View more
  4 in total

Review 1.  Cannabis use and cannabis use disorder.

Authors:  Jason P Connor; Daniel Stjepanović; Bernard Le Foll; Eva Hoch; Alan J Budney; Wayne D Hall
Journal:  Nat Rev Dis Primers       Date:  2021-02-25       Impact factor: 52.329

2.  Cannabinoid reward and aversion effects in the posterior ventral tegmental area are mediated through dissociable opiate receptor subtypes and separate amygdalar and accumbal dopamine receptor substrates.

Authors:  Tasha Ahmad; Steven R Laviolette
Journal:  Psychopharmacology (Berl)       Date:  2017-07-01       Impact factor: 4.530

3.  Cannabis Withdrawal: A Review of Neurobiological Mechanisms and Sex Differences.

Authors:  Nicolas J Schlienz; Alan J Budney; Dustin C Lee; Ryan Vandrey
Journal:  Curr Addict Rep       Date:  2017-04-29

Review 4.  Epigenetic Effects of Drugs of Abuse.

Authors:  Thomas Heinbockel; Antonei B Csoka
Journal:  Int J Environ Res Public Health       Date:  2018-09-25       Impact factor: 3.390

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.